Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2019, the company owned and operated 472 care centers in 38 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.
Industry, Sector and Symbol
Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Phone225-292-2031
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.66 billion
Profitability
Miscellaneous
Employees21,000
Next Earnings Date7/30/2019 (Estimated)
OptionableOptionable
Amedisys (NASDAQ:AMED) Frequently Asked Questions
What is Amedisys' stock symbol?
Amedisys trades on the NASDAQ under the ticker symbol "AMED."
How were Amedisys' earnings last quarter?
Amedisys Inc (NASDAQ:AMED) announced its quarterly earnings results on Tuesday, April, 30th. The health services provider reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.89 by $0.22. The health services provider earned $467.34 million during the quarter, compared to the consensus estimate of $460.83 million. Amedisys had a return on equity of 28.25% and a net margin of 7.14%. Amedisys's revenue for the quarter was up 17.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.79 EPS. View Amedisys' Earnings History.
When is Amedisys' next earnings date?
What guidance has Amedisys issued on next quarter's earnings?
Amedisys issued an update on its FY19 earnings guidance on Tuesday, April, 30th. The company provided earnings per share (EPS) guidance of $3.98-4.09 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.02. The company issued revenue guidance of $1.94-1.98 billion, compared to the consensus revenue estimate of $1.96 billion.Amedisys also updated its FY 2019 guidance to $3.98-4.09 EPS.
What price target have analysts set for AMED?
12 Wall Street analysts have issued 12-month target prices for Amedisys' shares. Their forecasts range from $78.00 to $145.00. On average, they anticipate Amedisys' share price to reach $123.8033 in the next year. This suggests a possible upside of 12.5% from the stock's current price. View Analyst Price Targets for Amedisys.
What is the consensus analysts' recommendation for Amedisys?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 8 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amedisys.
Has Amedisys been receiving favorable news coverage?
News coverage about AMED stock has trended somewhat positive on Monday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amedisys earned a news sentiment score of 0.7 on InfoTrie's scale. They also assigned media stories about the health services provider a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future.
Who are some of Amedisys' key competitors?
What other stocks do shareholders of Amedisys own?
Who are Amedisys' key executives?
Amedisys' management team includes the folowing people:
- Mr. Paul Berthold Kusserow, Pres, CEO & Director (Age 58)
- Mr. Scott G. Ginn, Chief Financial Officer (Age 50)
- Mr. Christopher T. Gerard, Chief Operating Officer (Age 52)
- Mr. David L. Kemmerly, Sr. VP of Gov. Affairs & Gen. Counsel (Age 56)
- Ms. Sharon Brunecz, Chief HR Officer (Age 52)
Who are Amedisys' major shareholders?
Amedisys' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.08%), Wellington Management Group LLP (3.73%), JPMorgan Chase & Co. (2.83%), Dimensional Fund Advisors LP (2.76%), Acadian Asset Management LLC (2.25%) and Northern Trust Corp (1.46%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Linda J Hall, Michael Paul North and Scott G Ginn. View Institutional Ownership Trends for Amedisys.
Which institutional investors are selling Amedisys stock?
AMED stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Dimensional Fund Advisors LP, Goldman Sachs Group Inc., Principal Financial Group Inc., Wellington Management Group LLP, Renaissance Technologies LLC and Acadian Asset Management LLC. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Linda J Hall, Michael Paul North and Scott G Ginn. View Insider Buying and Selling for Amedisys.
Which institutional investors are buying Amedisys stock?
AMED stock was acquired by a variety of institutional investors in the last quarter, including Man Group plc, Marshall Wace LLP, AJO LP, Northern Trust Corp, American International Group Inc., Columbus Circle Investors, The Manufacturers Life Insurance Company and AQR Capital Management LLC. View Insider Buying and Selling for Amedisys.
How do I buy shares of Amedisys?
Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amedisys' stock price today?
One share of AMED stock can currently be purchased for approximately $110.07.
How big of a company is Amedisys?
Amedisys has a market capitalization of $3.53 billion and generates $1.66 billion in revenue each year. The health services provider earns $119.35 million in net income (profit) each year or $3.63 on an earnings per share basis. Amedisys employs 21,000 workers across the globe.
What is Amedisys' official website?
How can I contact Amedisys?
Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]
MarketBeat Community Rating for Amedisys (NASDAQ AMED)
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe AMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
